Janux Therapeutics, Inc. (JANX) Stock Price & Analysis

Janux Therapeutics, Inc. (JANX) rose 0.81% to USD 13.62 as of June 10, 2026 at 02:01 UTC, according to Nexqual real-time market data.

JANX last closed at USD 13.51; the session ranged USD 13.28–13.88 on volume of 488,132 shares. Market capitalization is $830.61M, with a 52-week range of USD 12.12–35.34 (NGM). Source: Nexqual, June 10, 2026 at 02:01 UTC.

Key Statistics (as of June 10, 2026 at 02:01 UTC)

Technical Analysis (JANX)

Nexqual's technical model rates JANX "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:01 UTC.

Analyst Ratings (JANX)

Wall Street analysts rate JANX "None" based on 16 analysts, with a mean price target of USD 40.56 (range USD 14–80), per Nexqual as of June 10, 2026 at 02:01 UTC.

Earnings (JANX)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 02:01 UTC.

Financials & Fundamentals (JANX)

Source: Nexqual, June 10, 2026 at 02:01 UTC.

Financial Health Score (JANX)

Nexqual rates Janux Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:01 UTC.

Ownership (JANX)

Source: Nexqual, June 10, 2026 at 02:01 UTC.

Leadership (JANX)

Janux Therapeutics, Inc. is led by David Alan Campbell (age 65), President, Co-Founder, CEO & Director, per Nexqual as of June 10, 2026 at 02:01 UTC.

Major Backers & Investors (JANX)

Notable institutional backers of Janux Therapeutics, Inc. include RA Capital Management, L.P., Janus Henderson Group PLC, Prosight Management, Lp, according to Nexqual as of June 10, 2026 at 02:01 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 02:01 UTC.

From Janux Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• For example, our proprietary technology allows the masking and tumor activation of different T cell therapy modalities, including costimulation via CD28 engagement and our TRACIr platform.
• We are also applying our proprietary technology to create molecules designed to attract, redirect, or mobilize different types of immune cells to tumor sites that exclude or lack resident immune cells. 8 Table of Contents   • Utilize our expertise in TCEs to redesign novel bispecifics and expand pipeline beyond cancer.
• We developed our proprietary albumin-binding domain derived from a llama antibody optimized for its ability to bind to albumin from both humans and NHPs, the primary preclinical species in which we conduct our in vivo experiments due to the similarity in target sequences and immune function with humans.
• This continuous infusion dosing regimen represents a significant burden for patients.   Our TRACTr and TRACIr platforms‌ We believe our proprietary TRACTr and TRACIr platforms offer the potential to expand the breadth of patients that can be treated with TCEs and non-TCE based immunomodulators while reducing the risk of life-threatening toxicities.

Partnerships

• In August 2025, we announced the first patient dosed in the lead collaboration program.   Our Collaboration with Bristol Myers Squibb   In January 2026, we entered into an exclusive license and collaboration agreement with Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types.
• In December 2020, we entered into a research collaboration and exclusive license agreement with Merck to develop TRACTr product candidates distinct from those in our internally developed pipeline.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:01 UTC. This page is informational and not investment advice.